Clinical trials: Antiviral Treatment
Coronavirus Disease 2019 (COVID-19)
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
This study evaluates the efficacy and safety of efprezimod alfa in hospitalized adult participants who are diagnosed with coronavirus disease 2019 (COVID-19) and receiving oxygen support.
- Trial name
- SAC-COVID (NCT04317040)
- Testing
- Efprezimod alfa
- Where
- 10 sites in United States
- Volunteers
- 234 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hepatitis C Virus
A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
The purpose of this study was to evaluate the efficacy, safety and pharmacokinetics of ABT-450/r when given together with ABT-267 and with and without RBV in treatment-naïve participants with genotype 1, 2 or 3 chronic HCV…
- Trial name
- Navigator (NCT01458535)
- Testing
- ABT-450, ABT-267, ribavirin
- Volunteers
- 61 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections
3TC (Lamivudine; GR109714X) Open-Label Program
To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies.
- Trial name
- NCT00002108
- Testing
- Lamivudine, Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
COVID-19 Respiratory Infection, SARS-CoV2 Infection
Echinaforce COVID-19 Shedding Study
Respiratory viruses pose a permanent threat to humans and society as demonstrated by the current Covid-19 pandemic. Novel drugs and vaccines provide a means for controlling illness.
- Trial name
- NCT04999098
- Testing
- Echinaforce Forte tablets, Echinaforce Chewable tablets, Echinaforce tincture
- Where
- Bulgaria
- Volunteers
- 40 people
- Sponsor
- A. Vogel AG
Hepatocellular Carcinoma, Hepatitis B Virus
Effects of Antiviral Therapy on Patients With HBV-related HCC
Based on the follow-up data of patients who underwent hepatectomy for HBV-related HCC at the First Affiliated Hospital of Xi'an Jiaotong University.
- Conditions
- Hepatocellular Carcinoma, Hepatitis B Virus, Survival
- Trial name
- NCT05406089
- Testing
- Medication history
- Volunteers
- 494 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepatitis C
Hepatitis C Rimantadine and Antiviral Combination Therapy
Hepatitis C virus is one of the leading causes of liver failure and liver cancer worldwide. Current treatment of hepatitis C infection is only successful in about half of those who are eligible.
- Trial name
- HepRiACT (NCT01413490)
- Testing
- rimantadine
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
2019-nCoV
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment…
- Trial name
- NCT04255017
- Testing
- Abidol hydrochloride, Oseltamivir, Lopinavir/ritonavir
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tongji Hospital
HIV Infection, Hepatitis C
A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects
The purpose of this study is to determine whether a simplified lopinavir/ritonavir-based therapy will continue to keep the viral load at very low levels after initial treatment with a combination of Kaletra (lopinavir/ritonavir)…
- Trial name
- NCT00121017
- Testing
- Kaletra (lopinavir/ritonavir), Sustiva (efavirenz), Truvada (emtricitabine/tenofovir disoproxil fumarate)
- Volunteers
- 200 people
- Sponsor
- Abbott
Hepatitis B, Chronic
Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients
This is a randomized, open label, phase IV, multicenter study for efficacy and safety of lamivudine versus entecarvir therapy in HBV-related advanced liver disease patients with high viral load and normal or slightly elevated…
- Trial name
- NCT00823550
- Testing
- Entecavir, Lamivudine
- Where
- South Korea
- Volunteers
- 462 people
- Sponsor
- Yonsei University
HIV Infections
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood.
- Trial name
- NCT00028301
- Testing
- Atazanavir, Lopinavir/Ritonavir
- Where
- 97 sites in United States, Argentina and 13 more
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Viral Infection, Chronic Hepatitis C
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 alone or in combination with other antivirals for a 12-week treatment duration in treatment-naïve participants with genotype…
- Conditions
- Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
- Trial name
- NCT02716428
- Testing
- Faldaprevir, TD-6450, Ribavirin
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 25 people
- Sponsor
- Trek Therapeutics, PBC
Hepatitis C, Hepatitis C, Chronic
Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy Patients
This is a pilot feasibility study of a small randomized controlled trial (RCT)design to evaluate participation in a Cognitive Behavioral Coping Skills (CBCS) group intervention versus standard of care in patients with hepatitis C…
- Trial name
- NCT03057236
- Testing
- Cognitive Behavior Coping Skills
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Primary Liver Cancer
Efficacy and Significance of Antiviral Therapy for Unresectable Hepatitis B Virus-related Primary Liver Cancer
This study is working to research the efficacy and significant of the anti-virus therapy in the unresectable Hepatitis B virus (HBV) related primary liver cancer(PLC) so as to establish treatment standards of anti-virus therapy…
- Trial name
- NCT00824707
- Testing
- Entecavir, conventional therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
HIV
Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC
The primary objective of this study in antiretroviral (ARV)-naïve Human immunodeficiency virus 1 (HIV-1) ribonucleic acid infected subjects is to compare the response rate at Week 48 of a daily regimen of Atazanavir (ATV)/…
- Trial name
- NCT01620944
- Testing
- Atazanavir, Ritonavir, Lamivudine
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma
SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002571
- Testing
- bleomycin sulfate, filgrastim, cyclophosphamide
- Where
- 85 sites in United States
- Volunteers
- 52 people
- Sponsor
- SWOG Cancer Research Network
HIV Treatment, HIV Prevention
HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots
The goal of this observational study is to establish an operational framework for home self-collections of blood samples to be used for antiviral drug concentration measurements.
- Trial name
- HOME-1 (NCT04979728)
- Testing
- At Home Self-Collections
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Colorado, Denver
Hepatitis C, Chronic
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
This study will investigate safety, antiviral activity, and pharmacokinetics of BI 201335 NA in HCV genotype 1 infected patients treated for 14 days monotherapy followed by BI 201335 NA combination therapy with PegIFN/RBV for an…
- Trial name
- NCT00793793
- Testing
- BI201335
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 96 people
- Sponsor
- Boehringer Ingelheim
HIV Infection
Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection
This study will try to define how and where HIV infection persists in the body by determining: 1) if there are cells where HIV can live for long periods of time without being seen and destroyed by the immune system; 2) if there…
- Trial name
- NCT00001644
- Testing
- Indinavir, Zidovudine, Lamivudine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis C
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
The purpose of this study is to see if treatment with PEG-interferon-alfa-2a (PEG-IFN) plus ribavirin is a more effective treatment for hepatitis C virus (HCV) than interferon-alfa-2a (IFN) plus ribavirin for patients infected…
- Trial name
- NCT00008463
- Testing
- Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
- Where
- 24 sites in United States
- Volunteers
- 132 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults
Effective, suppressive treatment for HIV infected patients can be a major challenge because HIV progressively destroys their immune systems.
- Trial name
- NCT00110578
- Testing
- Adoptive transfer of HIV-specific CD8+ T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)